COST-EFFECTIVENESS OF THE KETANSERIN VS. SULFADIAZINE ON THE PATIENT WITH DIABETIC FOOT

Abstract

Objective. Determine the cost-effectiveness of the ketanserin vs. sulfadiazine on the patient with diabetic foot. Methodology. Study of the cost effectiveness on patients with diabetic foot, there were integrated two groups; the ones managed with ketanserin (n=50), and the ones managed with sulfadiazine (n=30), all that came to the service were included. The cost contemplates the inputs for the cure and the medication. The effectiveness was measured with the reduction of the injury measured in centimeters and the cured patient’s percent. Sensitivity and incremental analysis was performed. Results. The cost of square centimeter of healing in ketanserin is $22.43 US and in the sulfadiazine $120.44 US. The cost of 5000 patients whit an 10 centimeter injury is $1,121,651 US in ketanserin and $6,021,787 US in sulfadiazine. Conclusion. The relation cost-effectiveness of the ketanserin is
better than the sulfadiazine one in the management of the diabetic foot.